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Although systole was for long considered the core of cardiac function, hemodynamic performance is evenly dependent
on appropriate systolic and diastolic functions. The recognition that isolated diastolic dysfunction is the major culprit for
approximately ﬁfty percent of all heart failure cases imposes a deeper understanding of its underlying mechanisms so that better
diagnostic and therapeutic strategies can be designed. Risk factors leading to diastolic dysfunction aﬀect myocardial relaxation
and/or its material properties by disrupting the homeostasis of cardiomyocytes as well as their relation with surrounding matrix
and vascular structures. As a consequence, slower ventricular relaxation and higher myocardial stiﬀness may result in higher
ventricular ﬁlling pressures and in the risk of hemodynamic decompensation. Thus, determining the mechanisms of diastolic
function and their implications in the pathophysiology of heart failure with normal ejection fraction has become a prominent
ﬁeld in basic and clinical research.
1.Introduction
From the earliest stages of an individual’s life, the heart
has the challenging mission to uninterruptedly transfer its
kinetic energy to the blood. This task is accomplished
by means of its intrinsic mechanical activity, which can
be considered as being composed of two continuous and
interdependent functions: systole and diastole. Being a living
structurewithbiomechanicalsensing features[1]theheartis
a paradigmatic organ of continuous mechanical adaptation
[2]. In this way, it is able to adapt its intrinsic mechanical
properties when diﬀerent loads and neurohumoral condi-
tions are imposed so that new mechanical and biological
steady states may be eventually achieved [1, 3, 4]. However,
permanent pathologic stimuli make this equilibrium at best,
short-termed, imposing an imbalance towards a progressive
impairment of cardiac function and inexorably leading to a
dysfunctionalphenotype.Thisprocessconsistsofbothintra-
and extracellular remodeling, with deleterious consequences
at structural, molecular, and functional levels.
Despite the knowledge that the heart spends almost
two-thirds of its time in diastole (relaxing and ﬁlling), its
contractile activity was for a long time considered the core of
its mechanical function and over which major concerns had
been focused. Indeed, it was not until the nineteen eighties
thatthescientiﬁccommunitybegantorealizetheclinicalsig-
niﬁcance of diastolic dysfunction among patients with signs
and symptoms of heart failure (HF) but in whom ejection
fraction was rather preserved. The recognition of the latter
condition as “heart failure with normal ejection fraction”
(HFNEF) impelled major eﬀorts in order to identify the
pathophysiological mechanisms underlying this emerging
concept. Female gender, older age, arterial hypertension,
diabetes, obesity, and left ventricular (LV) hypertrophy are
currently well-established risk factors [5–21], showing a
strong association with impaired diastolic function with
a concomitant normal or only mildly abnormal systolic
function. However, and according to the Heart Failure
and Echocardiography Associations of the European Society
of Cardiology, these patients are only classiﬁed as having
HFNEF if they develop signs or symptoms of HF along with
the objective recognition of normal systolic LV function and
of diastolic LV dysfunction [22]. Deserving special relief is
the fact that the therapeutic management of HFNEF is still2 Journal of Biomedicine and Biotechnology
relying on an empirical framework and is not translating
into any survival improvement in this particular group of
patients. However, it is currently not clear whether these
neutral outcomes are due to speciﬁc mechanisms in the
pathophysiology of HFNEF and/or to the nonadherence of
clinical trials to the existing diagnostic guidelines of HFNEF.
The latter has been recently shown to be responsible for
a high variability among the recruited patients in HFNEF
trials and therefore in their reported ﬁnal results [23, 24].
Importantly, a deeper understanding of the mechanisms
leading to the development of HFNEF as well as a systematic
compliance of the clinical trials to the current guidelines is
seriously warranted, setting the necessary conditions for an
eﬃcient cross-talk between clinical and basic research.
2. Risk Factors,DiastolicFunction, andHFNEF
Ithasbeendocumented thatLVstructureandfunctiondiﬀer
between HFNEF and HFREF [25], which may depend on the
relativeimpactthatassociatedclinicalconditionshaveonthe
development of a particular cardiac phenotype or disease.
Regarding HFNEF, female gender seems to be a major risk
factor for its development [16–20], not only by being more
frequently associated with other risk factors (e.g., arterial
hypertension) but also by rendering the postmenopausal
heart more susceptible to the remodeling features associated
with slower relaxation and lower ventricular compliance.
Even if the ﬁrst studies indicating a higher risk in females
[17, 26] have missed an objective evaluation of diastolic
dysfunction among the diagnosed cases, the conclusion that
such a trend may actually exist got early support from
clinical cardiologists. Indeed, recent epidemiological data
from the Framingham Heart Study [27] showed that within
the HF population studied (median age of HF onset of
78 years old), individuals with HFNEF were more likely to
be women (65% women versus 35% men), with an age-
adjusted odds ratio of 2.55 when compared to men. Arterial
hypertension or valvular heart disease also duplicated the
risk of developing HFNEF and both risk factors were more
frequent in women as well. Although this study showed that
survival was similar between genders and independent from
left ventricular ejection fraction (LVEF), results from the
CHARM program [28] indicated that women had a better
survival than men, even after adjustment for cause of heart
failure, LVEF, and age.
All these cumulative epidemiological data supporting
gender speciﬁcities in the risk of diastolic dysfunction and
HFNEF impelled basic research to study the mechanisms
underlying such diﬀerences, whose knowledge may con-
tribute to design more speciﬁc therapeutic targets and
guidelines for HF in general and HFNEF in particular. In
this regard, 17β-estradiol is a distinctive feature between
genders and has been shown to be an important modu-
lator of myocardial relaxation and passive properties [16].
Considering cardiomyocyte Ca2+-handling and relaxation,
17β-estradiol modulates the expression and activity of L-
type Ca2+ channels [29], the phosphorylation levels of
PLB [30], myoﬁlaments Ca2+ sensitivity [31]a n dp r o t e c t s
single cardiomyocytes against Ca2+ loading induced by
hypoxia [32]. Important mediators of 17β-estradiol within
the cardiovascular system and with recognized beneﬁts on
diastolic function are nitric oxide (NO) and endogenous
brain natriuretic peptide (BNP) whose levels are also higher
in females than in males [16]. By promoting the actions of
theseneurohumoralagents,estrogensmayincreasethespeed
of relaxation and ventricular compliance, improving overall
diastolic function. Beyond these acute and indirect eﬀects,
estrogens also modify myocardial material properties by
reducing cardiac ﬁbroblast proliferation, collagen turnover
and pressure overload-induced cardiomyocyte hypertrophy
[33, 34]. Therefore, it seems reasonable to speculate that
the loss of these beneﬁcial eﬀects after menopause may
render the female heart especially vulnerable to diastolic
dysfunction. Of special remark, the absence of the long-term
protective inﬂuences of estrogens confers a higher suscepti-
bilityofthefemalehearttotheriskfactorscommonlyleading
to HFNEF, such as obesity, hypertension, and diabetes [35,
36]. Actually, comparing individuals from both genders with
similar degrees of arterial hypertension or aortic stenosis,
women develop more often concentric cardiac remodeling
while males develop more often eccentric remodeling [35].
As concentric hypertrophy leads to increased wall thickness
and possibly smaller chambers, the resulting ventricular
geometry leads to earlier partial chamber ﬁlling, with
increases in operating stiﬀness [16]. The synergic eﬀects
of obesity and hypertension to the development of left
ventricular hypertrophy are much stronger in women than
in men as is greater the eﬀect of diabetes to the development
of congestive HF in the female gender [37].
Independently or in association, all these risk factors
may cause structural and functional changes at the organ,
cellular and molecular levels of the heart, leading to a slower
relaxationand/or increased chamberstiﬀness.Adetaileddis-
cussion on these determinants of diastolic function follows.
3.DiastolicPropertiesof the Cardiac
Muscle—A Composite Material
Cardiac muscle tissue is a composite material consisting of
cardiomyocytes, ﬁbroblasts, blood vessels, and extracellular
matrix (ECM). Therefore, it is reasonable to postulate that
changes in any of the elements within the myocardium
may aﬀect its material properties [38] and, consequently,
its mechanical function. Both cellular and matrix structures
contribute to myocardial physical properties, based on their
intrinsicmechanicalfeatures,spatialandfunctionalrelations
with the surrounding structures and tissue geometry, which
ﬁnally ensues in the adult heart. Thus, when considering
heart biomechanical properties, we have to conceptually
integrate not only the single contribution of the various car-
diacmuscletissueelementsbutalsothecomplexinteractions
among them as well as their ability to modify their intrinsic
mechanics under diﬀerent pathophysiological conditions.
Considering the dynamic nature of diastole, it is not
surprising that myocardial material properties are a central
determinant of diastolic function and dysfunction. GenerallyJournal of Biomedicine and Biotechnology 3
Table 1: Determinants of diastolic function and myocardial stiﬀness.
Determinants of diastolic function
Myocardial relaxation
Load
Inactivation (calcium homeostasis, myoﬁlaments, energetics)
Nonuniformity
Passive properties of ventricular wall
Myocardial stiﬀness
Wall thickness
Chamber geometry
Other determinants
Structures surrounding the ventricle (pericardium, lungs, remaining, cardiac chambers)
Left atrium, pulmonary veins and mitral valve
Heart rate
Determinants of myocardial stiﬀness
Cardiomyocytes
Ca2+ homeostasis
Diastolic calcium concentration: residual cross-bridges
Cytoskeleton
Microtubules (tubulin) and intermediate ﬁlaments (desmin): density and cellular stiﬀness
Myoﬁlaments: actin and myosin (residual cross-bridges)
Titin: isoforms expression ratio; isoforms’ phosphorylation status
Extracellular matrix
Collagen: content, type, alignment, spatial distribution, cross-linking
Proteoglycans: putative role in interstitial water ﬂow and content within the myocardium
Elastin: putative decrease in elastin/collagen ratio with increased myocardial stiﬀness
deﬁned as the ability of the ventricle to relax and ﬁll [39],
diastolic function depends on active myocardial relaxation
and on passive properties. While relaxation is the process
whereby the myocardium returns to an unstressed length
and force, passive properties mostly inﬂuence the extent
of muscle relength and end-diastolic pressure-volume rela-
tionship (EDPVR). Although active myocardial relaxation is
responsible for its motion and blood ﬂow, it is only through
the perfect match of both active and passive properties
that overall diastolic function is preserved. For conceptual
purposes, myocardial passive properties are considered as
such because they are assessed after complete muscle relax-
ation, that is, a mostly energy-consuming and, hence, active
process. However, a growing body of evidence clearly shows
that myocardial passive properties might as well be actively
modulated and depend on cardiac high-energy phosphate
metabolism.
The contribution of both active and passive properties to
diastolic dysfunction and to the clinical syndrome of HFNEF
will be discussed in the next sections.
3.1. Relaxation and Its Physiological Modulators. In the
normal heart, myocardial relaxation comprises the major
part of ventricular ejection, pressure fall and the initial part
of rapid ﬁlling [39–42].
At the cellular level, the central players of the relaxation
process are the cardiomyocytes, whose homeostatic balance
is a major determinant in the maintenance of an appropriate
relaxation speed. In this way, any process interfering with
cardiomyocyte physiology may delay relaxation long enough
and signiﬁcantly impair LV diastolic ﬁlling, especially at
faster heart rates.
Conceptually, the determinants of ventricular relaxation
(either by disturbing diastolic cardiomyocyte performance
or by disrupting the synchrony of their actions) are load,
inactivation, and nonuniformity (Table 1)[ 39].
3.1.1. Load. The eﬀects of load depend on its type (preload
versus afterload), magnitude, duration, and timing in the
cardiac cycle at which it occurs [40]. For instance, severe or
late systolic afterload elevations are particularly eﬀective in
delaying relaxation rate, even in healthy hearts [43].
In the clinical setting, marked arterial hypertension is
a paradigmatic example of severe afterload imposition on
the left ventricle and is a major risk factor for myocardial
hypertrophy and failure. As relaxation in failing hearts
is especially vulnerable to load, increases in afterload
may signiﬁcantly delay relaxation and result in pulmonary
congestion in HF patients [44]. Taking into account that
neurohumoral activation takes place both in HFNEF and
HFREF, the failing heart in HFNEF is not only faced with
a higher afterload (increased peripheral vascular resistance)
but also with a higher preload (volume retention), further
increasing the odds of hemodynamic decompensation [45].4 Journal of Biomedicine and Biotechnology
Even if the underlying mechanisms are still unclear, changes
in the activity of Ca2+-handling proteins and myoﬁlaments’
sensitivity to this ion (e.g., troponin I) are the most likely
eﬀectors of the observed slower relaxation upon changes in
load [46–49].
3.1.2. Inactivation. Deserving special relief, inactivation
refers to the process underlying Ca2+ extrusion from the
cytosol and cross-bridge detachment. As abovementioned,
its importance stems from the fact that disturbances in
this process may represent the ultimate eﬀectors of several
pathophysiological conditions leading to impaired relax-
ation, including load [49].
In the healthy human heart, the pathways involved in
Ca2+ extrusion from the cytosol are the phospholambam-
modulated uptake of this ion by the sarcoplasmic reticulum
Ca2+ ATPase (SERCA2a, 70%), the Na+/Ca2+-exchanger
(28%), and, to a lesser extent, the Ca2+-pump and the
mitochondrial Ca2+ uniport (2%) [50]. Equally important
is the phosphorylation state of the proteins that regulate
SERCA2a activity, such as phospholambam (PLB), calmod-
ulin, and calsequestrin. PLB stands as a classic example of
a protein that interacts with and inhibits SERCA2a activity
in a reversible manner. Although its relevance in cardiac
physiology has been extensively studied over the last years,
there is now an emerging ﬁeld of interest focusing on the
structurally-related protein sarcolipin (SLN). Most notably,
this protein is absent in the ventricles but is signiﬁcantly
expressed in the atria, which may indicate the existence
of chamber-speciﬁc mechanisms of SERCA2a function reg-
ulation. Nonetheless, overexpression of sarcolipin in mice
ventricularmyocyteswasfoundtoinhibitSERCA2abydirect
binding or through stabilization of the interaction between
SERCA2a and phospholamban [51, 52]. As a consequence,
the aﬃnity of SERCA2a for calcium was decreased, calcium
transients amplitude was lower, and the time of calcium
decay and relaxation was signiﬁcantly extended [53, 54].
Despite the atrial-speciﬁc expression of SLN and the higher
expression of PLB in the mouse ventricle, SLN expression
may not be conﬁned to the atria in other species [54]a n d
possibly in pathological conditions, such as heart failure.
Besides the importance of the aforementioned mecha-
nisms concerning the velocity and extent of Ca2+ reuptake
into the SR, it has been proposed that diastolic Ca2+ leakage
from the ryanodine receptor (associated with diminished FK
506-binding protein 12.6) may also increase diastolic Ca2+
levels and contribute to a higher thick-thin ﬁlament interac-
tion and delayed relaxation [55]. Therefore, the functional
integrity of the SR must translate not only in an eﬀective
reuptake but also a subsequent diastolic sequestration of
Ca2+.
As relaxation is an energy-consuming process, high-
energyphosphatemetabolismisacenterpieceinseveralsteps
involvedinthisphaseofdiastole,namely,inCa2+dissociation
from troponin C, myosin-actin detachment, active seques-
tration of Ca2+ into the SR, and in several phosphoryla-
tion reactions of Ca2+-handling proteins [46]. Indeed, any
energetic imbalance leading to an abnormally high ADP
concentration or ADP/ATP ratio is associated with slower
relaxation rates and increased diastolic stiﬀness [39]. Besides
slower Ca2+ transients’ decay, a higher sensitivity of the
myoﬁlament proteins to this ion might as well decrease
the pace of myocardial relaxation. An important example
is cardiac troponin-I (cTnI) which is less phosphorylated
in HFREF and therefore shows a higher sensitivity to Ca2+
[56]. As a result, comparable increases in Ca2+ concentration
may result in greater myoﬁlaments’ activation and enhanced
myocardial contractility. However, as corroborated by the
recent ﬁndings of Yasuda et al., the ﬂip side of the coin
may be a delay in myocardial relaxation and a consequent
increase in diastolic stiﬀness. In the latter study, both in vitro
and in vivo experiments designed to engineer sarcomeres
with a PKA nonphosphorylatable TnI or a PKA phospho-
mimeticofcardiacTnIindicatedanimportantroleofcardiac
TnI phosphorylation status in regulating cardiomyocyte
relaxation velocity [57].
3.1.3. Nonuniformity. Nonuniformity represents asynchro-
nous changes in ventricular shape during contraction and
relaxation, being most frequent in the setting of coronary
artery disease and intraventricular conduction disturbances.
During isovolumic relaxation, it may be represented by reex-
tension of one ventricular segment accompanied by post-
systolic shortening of another, generating an asynchrony
in ventricular relengthening and possibly in ventricular
pressure fall. Consequently, this may further contribute to
diastolic dysfunction [39].
Most, if not all, the risk factors pointed to be associated
with HFNEF invariably lead to impaired relaxation, even if
somemaybeespeciallyinvolvedinmodifyingthemyocardial
passive properties. However, unraveling the mechanisms
through which a single risk factor induces diastolic dysfunc-
tion/HFNEF has been a challenging task due to the high
prevalence of several comorbidities among HF patients. The
latter condition promotes the interaction among the existent
risk factors, which may signiﬁcantly modify the phenotype
of the disease, its clinical presentation, and prognosis.
3.2. Ventricular Passive Properties and Their Physiological
Modulators. Although active properties of the myocardium
are responsible for its motion and blood ﬂow, overall dias-
tolic function is stringently dependent on the maintenance
of adequate passive properties as well. Indeed, current data
strongly associates changes in myocardial material properties
and various forms of heart disease. The passive properties
of the ventricular wall depend on myocardial stiﬀness, wall
thickness,andchambergeometry(Table 1)andareevaluated
by observing the position and shape of the EDPVR [39].
This is an exponential curve which is derived by plotting
the lower right corner of multiple pressure-volume (PV)
loops at various preloads. Considering the three-parameter
monoexponentialformula(P = P0 + A∗ekc
∗V),theEDPVR
is dependent on ventricular distensibility (represented by
changes in vertical position, i.e., in the value of the pressure
intercept P0), ventricular size (represented by changes in
horizontal position, that is, in constant A), and ventricularJournal of Biomedicine and Biotechnology 5
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Figure 1:Schematicrepresentationoftheend-diastolicpressure-volumerelationship(EDPVR)intheabsence(a)orpresence(b)ofdiastolic
dysfunction. The dashed segment of the EDPVR represents the pressure-volume interval in which an individual remains hemodynamically
stable. In (b), the steeper EDPVR narrows the ventricular pressure-volume interval and increases the individual’s susceptibility to
hemodynamic decompensation.
compliance (represented by changes in the slope of the curve,
i.e., in the modulus of chamber stiﬀness, Kc).
Due to the concentric hypertrophy and stiﬀer myocardial
wallcommonly associated with HFNEF, the hallmarksof this
condition are decreased distensibility, decreased compliance,
and smaller cavity size. As a consequence, the ventricular
wall displays stronger elastic forces resisting expansion
during diastolic ﬁlling, which is translated into an upward
and leftward shift of the EDPVR, that is, into a steeper
relation.Indeed,changesinitsslopedeservespecialemphasis
as it reﬂects the patient’s vulnerability to hemodynamic
decompensation,regardlessoftheHFphenotype(HFNEFor
HFREF) and ventricular cavity size [45].
As depicted in Figure 1, the slope of the curve at
operating conditions is a valuable surrogate of these patients’
clinical susceptibility: the steeper the curve, the smaller the
volume variation capable of markedly increasing ventricular
ﬁlling pressures and inducing pulmonary congestion.
However, we must bear in mind that the EDPVR is
not solely dependent on intrinsic passive properties of
the ventricular wall but also on extrinsic factors (e.g.,
pericardium, lungs) [39, 46] as well as conditions leading to
incomplete myocardial relaxation, such as severe tachycardia
in HF patients (Table 1). The latter situation is especially
important because their hearts may exhibit a ﬂat or even
negative relaxation velocity-versus-heart rate relationship
[58]. In this way, when heart rate increases, relaxation rate
does not increase or even decreases, leading to a stiﬀer
ventricle in late diastole and hence higher ﬁlling pressures.
3.2.1. Myocardial Stiﬀness. Considering the importance of
myocardial material properties in determining ventricular
compliance and clinical severity of HFNEF, their study
became an attractive ﬁeld in HF research. In further sec-
tions, there will be emphasized the relative contribution of
cardiomyocytesandextracelularmatrixtooverallmyocardial
stiﬀness, both in physiological and pathological conditions
(Table 1).
4. CardiomyocytesandMyocardial
Material Properties
Several studies have shown that changes in myocardial
material properties can be caused by mechanisms intrinsic
to the cardiomyocytes themselves [38, 59–68]. These include
mechanisms that may alter (i) the relative content, (ii)
the isoforms expression, (iii) posttranslational modiﬁcations
and/or (iv) active interactions among the cytoskeletal struc-
tures of cardiac cells, thus aﬀecting the overall resistance to
changes in shape.
The cardiomyocyte cytoskeleton is composed of micro-
tubules(tubulin), intermediate ﬁlaments (desmin), microﬁl-
aments (actin), and endosarcomeric proteins, of which titin
has lately received particular attention.
4.1. Microtubules and Intermediate Filaments. At operating
sarcomere lengths (1.9–2.2 μm), microtubules and inter-
mediate ﬁlaments were found to contribute less than
10% to passive tension [67]. However, in the setting of
right-ventricular pressure overload hypertrophy (RVPOH)
and at physiological rates of muscle length variation,
there is a higher resistance to changes in cardiomy-
ocyte shape, a result that is signiﬁcantly attenuated when
microtubules are chemically or physically depolymerized.
Thus, although microtubules may not signiﬁcantly con-
tribute to myocardial stiﬀness both in healthy states and
in slowly stretched muscles, their increased density may
play a role under pressure-overloaded conditions and at
physiological rates of contraction and relaxation [60, 67].
In these conditions, microtubules are mainly responsible
for an increase in cardiomyocyte resistance when rapidly
stretched.
4.2. Myoﬁlaments. Since the interaction between actin and
myosin was shown to occur even at low diastolic calcium
levels, it was hypothesized that the establishment of residual6 Journal of Biomedicine and Biotechnology
diastolic cross-bridges might as well mediate myocardial
passive stiﬀness [46]. As described for microtubules, Zile
and colleagues also showed that, in pressure-overloaded
conditions, there is a correlation between increased myocar-
dial stiﬀness, higher intracellular calcium concentration,
and increased number of cross-bridge interactions [38].
Therefore, changes in calcium transients or myoﬁlament’s
calcium-sensitivitymayincreasemyocardialstiﬀness[46,69]
even if these are most commonly regarded as determinants
of myocardial relaxation rate. The latter ﬁndings mean that
beyond the biophysical properties of structural cytoskeletal
proteins, cardiomyocyte stiﬀness may also be under active
control, thus evoking the concept of active muscle tone
[46].
4.3. Titin. Over the last decade, the contribution of the
endosarcomeric protein titin in the modulation of myocar-
dial stiﬀness has been elucidated. However, its relevance
in cardiac function goes beyond the scaﬀold and passive
force generating properties, being an important regulator of
systolicfunction[70,71],amechanotransducerincardiomy-
ocytes [72], and a central player in cardiac development,
growth, and hypertrophy [73–75].
4.3.1. Titin Isoforms and Myocardial Stiﬀness. Titin spans
the half-sarcomere from the Z-disk to M-line and its ability
to generate passive tension is associated with extensible
segments in the I-band of sarcomeres, comprised of serially
linked but distinct domains: the proline-glutamate-valine-
lysine (PEVK) element, immunoglobulin-(Ig-)like domains
and the segment with unique aminoacid sequences called
N2B, N2A, or N2BA (which contains both N2B and
N2A) [46, 59, 61, 63, 76]. It is expressed in the heart as
two diﬀerent isoforms, the smaller and stiﬀer N2B, and
the larger and more compliant N2BA. While the former
expresses only the cardiac speciﬁc N2B domain, the latter
expresses both N2B and N2A as well as additional PEVK
and Ig domains. Upon application of a longitudinal force,
stretch of cardiomyocytes within physiological sarcomere
length ranges is accompanied by unfolding of the PEVK, Ig
domains, and unique sequences N2A and/or N2B, resulting
in the generation of passive force. Upon release, these spring
elements tend to refold and achieve a state of lower contour
length and higher entropy. Given the presence of additional
segments in the N2BA titin isoform, it can accommodate
longer variations in length for the same levels of passive
force generated, being therefore more compliant than N2B
isoform. However, because these isoforms are coexpressed
in the same half sarcomere in a ratio that varies among
species and in diﬀerent locations within the heart, titin-
basedcardiomyocytestiﬀnessisusuallyanywherein-between
of that generated by N2B- or N2BA-purely expressing
cells. Accordingly, the predominant expression of N2B in
rodents [46, 69] accounts for a high cardiomyocyte stiﬀness,
while the more abundant expression of N2BA in large
mammals (pig, cow, human) accounts for a comparably
lower passive stiﬀness. However, and regardless of the animal
species, myocardial stiﬀness undergoes signiﬁcant changes
during physiological and pathological conditions, which are
partially accounted by shifts in titin isoforms expression
ratio as well as titin posttranslational modiﬁcations. The
earliest and probably the most robust shift occurs during the
perinatal period. In the fetal myocardium of mice, rats, and
pigs, titin is predominantly expressed as a compliant N2BA
titin isoform (fetal cardiac titin), which is characterized by
the presence of additional Ig and PEVK segments in its
extensible region than the adult N2BA titin [77]. Around
birth,thisfetalisoformisdownregulatedandtitintranscripts
are translated into a shorter, less extensible N2BA protein,
together with the onset N2B titin isoform expression. With
a time course that varies among species, N2B becomes the
predominant isoform in the adult heart, including humans.
As a consequence, the highly compliant fetal myocardium
becomes progressively stiﬀer and better adapted to higher
ventricular end-diastolic pressures that accompany post-
natal cardiac growth. Even in adulthood, titin isoforms
expression ratio is highly dynamic and contributes to
changes in myocardial stiﬀness upon pathological insults.
However, the direction of isoform shift is not consistent
among studies and the mechanisms that may lead to one
type of switch over another in HF remain unclear [46,
59]. A plausible explanation for these discrepancies relies
on the diﬀerent experimental/clinical contexts where the
shift in titin isoforms expression was studied, mostly likely
on diﬀerences in the nature, severity, and duration of the
disease. As depicted in Figure 2, the development of HF
or HF-associated pathological conditions is accompanied
by an increase in myocardial stiﬀness (Figure 2(a)), where
remodeling of the ECM invariably leads to a higher collagen-
based stiﬀness (Figure 2(b)). However, while in 2 canine
models of pacing-induced dilated cardiomyopathy (DCM)
[78, 79] the increase in myocardial stiﬀness with HF
was accompanied by a higher expression of the stiﬀ N2B
titin isoform (Figure 2(c)), the opposite was observed in
HF human hearts, either with normal [80] or reduced
ejection fraction [81–83]. (Figure 2(d)). In these studies,
the net increase in myocardial stiﬀness was accounted
by a higher collagen-based stiﬀness and/or changes titin
isoforms phosphorylation ratio. The observed increase in
N2BA/N2B expression ratio has been rather interpreted as
a compensatory mechanism in which the presence of more
compliant titin isoforms counteracts the progressive increase
in myocardial stiﬀness and diastolic dysfunction. Similar
ﬁndings in titin isoforms shift have been recently reported
in long-term hypothyroidism, a condition commonly associ-
ated with diastolic dysfunction [84]. Of note, Figure 2 does
not take into consideration the relative proportions of N2B
and N2BA titin isoforms but rather the main direction of
their shift, as reported in several studies.
4.3.2. Titin Posttranslational Modiﬁcations and Myocardial
Stiﬀness. Besidesthemolecularstructureandrelativeexpres-
sion ratio, posttranslational modiﬁcations of titin isoforms
(through either phosphorylation or calcium binding eﬀects)
may signiﬁcantly impact myocardial stiﬀness. N2B titin’s
segment was shown to be the target for protein kinase AJournal of Biomedicine and Biotechnology 7
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Figure2: Progressiveincreaseinmyocardial(a)andcollagen-based
stiﬀness (b) during physiologic cardiac growth as well as HF or
HF-associated pathological conditions. The increase in myocardial
stiﬀnesscanbeparalleledbyaconcordantincreaseintheexpression
of the stiﬀ titin isoform N2B (c) or by a compensatory increase in
the expression of the compliant titin isoform N2BA (d). Relative
hypophosphorylation of the stiﬀ N2B titin also accounts for an
increase in myocardial stiﬀness in HF, especially in HFNEF (e) (P-
N2B: phosphorylated N2B; P-N2BA: phosphorylated N2BA).
(PKA) and protein kinase G (PKG) phosphorylation [61, 76,
85–87], which possibly destabilizes its structure and induces
an increase in N2B segment length, thus reducing cardiomy-
ocyte passive tension. Because N2B element is included in
all cardiac titin isoforms, its extension is predicted to reduce
passive stiﬀness of both N2B and N2BA titins. However,
the magnitude of the phosphorylation-induced decrease in
passive stiﬀness is isoform dependent, because the shorter
N2Btitinmakesitsincreaseinlengthtohaveagreaterimpact
on its fractional extension. Accordingly, a relative deﬁcit in
N2B titin phosphorylation status was found to signiﬁcantly
raise cardiomyocyte stiﬀness in failing human myocardium
(Figure 2(e)), despite the compensatory increase in N2BA
titin isoform expression and phosphorylation. Interestingly,
patients with HFNEF had not only more N2B titin protein
(i.e., stiﬀer) but also less phosphorylated N2B titin (i.e.,
stiﬀer) than HFREF patients, explaining both the signiﬁ-
cantly higher stiﬀness and the more pronounced decay in
of passive tension upon to PKA-mediated phosphorylation
[80].
Titin phosphorylation by PKA and PKG clearly sup-
ports the eﬀects of β-adrenergic signaling and nitric oxide
in reducing cardiomyocyte stiﬀness, respectively [86, 87].
However, the association between titin phosphorylation by
Protein Kinase C (PKC) and the reported eﬀects of several
agonists of Gq protein-coupled receptors is not straight-
forward. As recently published, PKC phosphorylates titin’s
PEVK segment and leads to an increase in cardiomyocyte
stiﬀness[88,89]suggestingthattheadaptationofmyocardial
stiﬀness upon adrenergic stimulation may be ﬁnely regulated
by a balance between alpha and beta adrenergic receptors’
activation. However, acute activation of other Gq protein
coupled receptors (AT1, ETA, among others) has been
associated with a decrease in myocardial stiﬀness, an eﬀect
that was blunted when PKC was speciﬁcally inhibited [90,
91].WhetherabroadereﬀectofPKConthephosphorylation
status of cardiac myoﬁlaments, the isoform of PKC or
the simultaneous activation of other pathways may have
accounted for these results warrants further assessment.
Besides titin extention, diastolic stiﬀness may be also
produced by titin-calcium interactions in an isoform depen-
dent manner. Calcium binding directly increases the passive
stiﬀness of N2BA expressing myocardium by changes in its
structure but has no eﬀect on exclusively N2B expressing
myocardium. In the latter case, calcium exerts an indirect
eﬀect by promoting titin-actin interactions, which may serve
to retard thin ﬁlament sliding and contribute to myocyte
passive stiﬀness [59].
5.ExtraCellularMatrixandMyocardial
Material Properties
Besides cardiomyocytes, the ECM is another major determi-
nant of the myocardial material properties [92]. Among the
proteins within the ECM, ﬁbrillar proteins such as collagen
and elastin, proteoglycans, and the basement membrane
proteins each may play a role in determining the consti-
tutive properties of the myocardium [93, 94]. However,
collagen molecules have been hypothesized to be the most
important component within the ECM contributing to
myocardial stiﬀness and HFNEF [46], as it is a relatively stiﬀ
material with high tensile strength. However, its inﬂuence
on the stress-strain relation of the myocardium depends
on many factors including its concentration, ﬁbril and
ﬁber diameter, degree of crosslinking, spatial alignment,
and collagen types. In physiological conditions and at
sarcomere lengths less than 2.2 μm, the combined passive
ﬁber stiﬀness of the myocardium has been predominantly
attributed to intracellular structures, notably titin. However,
at longer sarcomere lengths, parallel collagen ﬁbers bear an
increasing fraction of the axial stress as collagen perimysial
ﬁbers untwist and straighten [94]. Interestingly enough,
the increase in myocardial stiﬀness across diﬀerent species
and heart chambers is associated not only to a higher
expression of the stiﬀ N2B titin isoform but also by a parallel
increase in collagen content, which suggests coordination
betweencollagensynthesisandtitinisoformexpression.This
might preserve the relative stiﬀness contributions of titin
(lower sarcomere lengths) and collagen (higher sarcomere
lengths) among species. However, this relationship may not
be preserved in pathological states [46]s u c ha sa r t e r i a l
hypertension,diabetes[95,96],ormyocardialinfarction[97,
98], because of their role in disrupting the balance between
collagen biosynthesis, degradation, and posttranslational
processing [46].8 Journal of Biomedicine and Biotechnology
6. Neurohumoral Modulation of Myocardial
MechanicalProperties
Besides mechanical inputs, growing evidence points to
neurohumoral agents such as nitric oxide (NO) [99–101],
angiotensin II [90, 102], endothelin-1 [91, 103, 104],
urotensin-II[105,106],andadrenomedullin[107]t oacu t el y
alter myocardial mechanical properties as well [108].
In isolated cardiomyocytes, NO was shown to shift the
stress-strain relation down and to the right. Accordingly,
intracoronary infusion of the exogenous NO donor, sodium
nitroprusside, resulted in a similar displacement of the end-
diastolic pressure-volume relation, both in normal and in
hypertrophiedhumanheartsasaresultPKG-mediatedphos-
phorylation of myoﬁlaments [101]. In further experiments,
substancePwasshowntopromotethereleaseofendogenous
NO, decreasing ventricular stiﬀness in patients with dilated
cardiomyopathy [39, 102]. Although some previous reports
[109] stated that higher coronary perfusion pressures might
cause an upward displacement of EDPVR by increasing
myocardial vascular engorgement, the latter results also
suggest that a simultaneous increase in endothelial shear-
stress may enhance the release of endogenous NO and
attenuate the aforementioned eﬀect. As titin is currently
known to be a target of PKG phosphorylation, an increase
in titin distensibility might have as well contributed to the
observed eﬀects [87].
Chronic activation of the renin-angiotensin system is
also a well-recognized mechanism that leads to increased
myocardial stiﬀness by promoting structural remodeling in
both cardiomyocytes and ECM. However, acute activation
of this system was shown to decrease myocardial and
ventricular chamber stiﬀness in a time frame that was
too short to alter the ECM [90]. Therefore, its eﬀects on
myocardial tissue must be caused by direct action on the
cardiomyocytes to alter one or more determinants of its
mechanical properties. Interestingly, a similar ﬁnding was
also ascribed to endothelin-1 in isolated papillary muscles
[91]. As angiotensin II and endothelin-1 exerted their eﬀects
through the activation of Gq Protein-Coupled Receptors
which are established activators of PKC signaling, further
studies are necessary to reconcile these observations with
the recently described PKC-mediated increase in titin and
cardiomyocyte stiﬀness.
7. Conclusion
The maintenance of normal diastolic performance is only
possible through the appropriate expression of cellular
and matrix phenotypes, which in turn are dependent on
the perfect match between the myocardial inputs and
its biological responses. Myocardial tissue is regarded as
composite material whose properties depend on each of
its speciﬁc constituent elements and the dynamic interplay
between their structure and function. In addition, the
biomechanical sensing features of the myocardium allow
it to alter its structural and functional phenotypes when
subjected to physiological inputs, thus achieving a new
biological equilibrium that preserves overall ventricular
function. In pathological settings, however, such equilibrium
can be easily disrupted, with both cardiomyocytes and ECM
exhibiting changes that may impair ventricular relaxation
and chamber stiﬀness. The growing knowledge about the
causal mechanisms of abnormal myocardial properties will
possibly allow us to diagnose earlier and choose the best
therapeutic strategies in patients with HF in general and
HFNEF in particular.
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